Results 91 to 100 of about 6,036 (190)

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

, 2011
The combination of glycoprotein IIb/IIIa inhibitors and heparin has not been compared with bivalirudin in studies specifically involving patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (PCI).
Kastrati, A;Neumann, FJ;Schulz, S;Massberg, S;Byrne, RA;Ferenc, M;Laugwitz, KL;Pache, J;Ott, I;Hausleiter, J;Seyfarth, M;Gick, M;Antoniucci, D;Schömig, A;Berger, PB;Mehilli, J
core   +1 more source

Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel or both?

Vascular Health and Risk Management, 2006
Matthew A Silva1, Jennifer L Donovan1,3, Pritesh J Gandhi2, Gregory A Volturo31Massachusetts College of Pharmacy and Health Sciences, Department of Pharmacy Practice, Worcester, MA, USA; 2Alexion Pharmaceuticals, Inc., Cheshire, CT, USA; 3UMass Memorial ...
Matthew A Silva, Jennifer L Donovan, Pritesh J Gandhi, Gregory A Volturo   +3 more
doaj  

Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).

, 2003
Early complications may hamper efforts to hasten discharge after primary percutaneous coronary intervention (PCI) for myocardial infarction (MI). Glycoprotein IIb/IIIa inhibitors, by reducing early recurrent ischemia, may aid in these efforts.
Tcheng, James E, Effron, Mark, Turco, Mark, Stuckey, Thomas, Carroll, John D, Kandzari, David E, Grines, Cindy L, Fahy, Martin, Cox, David A, Stone, Gregg W, Bakhai, Ameet, Cohen, David J, Griffin, John J, Mehran, Roxana   +13 more
core  

Influence of abciximab on the adhesion of platelets on a shielded plasma gradient prepared on polyethylene

, 2002
Introduction: Thrombotic effects of biomaterial implants are mediated merely through activation of the platelet glycoprotein IIb-Illa (GpIIb-IIIa) receptor.
Busscher, HJ, van Oeveren, W, Spijker, HT   +2 more
core   +1 more source

Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.

, 2001
Abciximab (c7E3) is the Fab fragment of the chimeric (murine/human) monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor, which is the final common pathway for platelet aggregation.
Salib, H, Nguyen, N, Mascarenhas, D A
core  

Antiagregantes plaquetarios: mecanismos de acción y riesgos asociados al uso Platelet antiaggregants: mechanisms of action and use asocied risks

Vitae, 2009
Las Enfermedades Cardiovasculares son la principal causa de muerte en el mundo. Junto con los esfuerzos en disminuir los factores de riesgo cardiovascular, se recurre a diversos medicamentos para disminuir la morbimortalidad asociada a estas enfermedades,
Iván F PALOMO G, Constanza I TORRES U, Rodrigo E MOORE-CARRASCO, Marcelo A ALARCÓN L, Patricio J MARAGAÑO L   +4 more
doaj  

Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation

Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary ...
Rachel H. Foster, Christopher J. Dunn
core  

Los inhibidores de los receptores plaquetarios IIb/IIIa en los síndromes coronarios agudos. The IIb/IIIa platelet receptor inhibitors in the acute coronary syndromes.

Revista Cubana de Cardiología y Cirugía Cardiovascular, 2001
Los inhibidores de los receptores IIb/IIIa, un nuevo grupo de antiagregantes plaquetarios, son potentes bloqueadores del receptor que media la agregación plaquetaria y de ese modo bloquean la vía final común de la formación del trombo plaquetario.
Fidel Manuel Cáceres Lóriga, Horacio Pérez López   +1 more
doaj  

An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates

, 2012
BACKGROUND: The ability of abciximab to prevent fibrinogen binding to activated platelets indicates it may also promote dissolution of platelet-rich thrombi.
Marciniak, Stanley J. Jr., Frelinger, Andrew L. III, Jordan, Robert E., Marchese, Peter J., Furman, Mark I., Jakubowski, Joseph A., Mascelli, Mary A., Michelson, Alan D.   +7 more
core  

PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS

Vitae, 2009
Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these diseases: antihypertensive, antidiabetic, hypolipemiant
Iván F. PALOMO G, Constanza I. TORRES U., Rodrigo E. MOORE-Carrasco., Marcelo A. ALARCÓN L., Patricio J. MARAGAÑO L.   +4 more
doaj